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1. Introduction
Soft tissue specimens from mummified remains of members of the Chinchorro culture of the 
Andean coast in South America have been found to be positive for Trypanosoma cruzi (T. cruzi) 
DNA [1]. The Chinchorros were fishermen inhabiting the pacific coastal region of northern 
Chile and southern Peru and T. cruzi the causative agent of American trypanosomiasis or 
Chagas disease is presently listed as one of the several neglected tropical diseases (NTDs) 
and as one of the five neglected parasitic infections (NPIs) of the world focused by the World 
Health Organization (WHO) and the Center for Disease Control (CDC) for public health inter-
vention [2]. This finding spells out that the causative agent of American trypanosomiasis has 
been around for 9000 years already as the samples which tested positive are dated back to 
7050 B.C. [1]. There are several historical accounts that have also mentioned about the preva-
lence of Chagas disease but some of these are just speculative assessments as signs and symp-
toms of patients were not consistent with the current pathophysiology of the disease. There 
were even speculations that Charles Darwin himself was infected with Chagas disease but 
popular opinions disagree as there were no actual clinical evidences to support that Charles 
Darwin was indeed suffering from megacolon or heart disease even later on in his life [3].
2. T. cruzi: a primeval pathogen
It was only in 1908 during an anti-malaria campaign in supporting a railway construction 
in the North of Minas Gerais that Carlos Chagas, a Brazilian physician (hygienist and bac-
teriologist) during his observations made this disease the center piece of his novel findings. 
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A  railroad engineer acquainted him with the presence of blood sucking insects in infested 
houses which preferentially were biting and taking blood meals on the face of occupancies 
in those mud huts during their sleep [4]. He identified the protozoan parasite T. cruzi in the 
bugs’ gut and later confirmed the presence in the blood samples of individuals who had a 
history of being bitten by this blood sucking bug. For this, scientific minds from his time to 
the present are indebted for the collection of knowledge he made possible in the process of 
understanding the disease, its agents, and its course in both human and animal hosts.
3. Transmission: a wide spectrum of dissemination modes?
Chagas disease or American trypanosomiasis is caused by a protozoan parasite T. cruzi 
mainly identified in blood samples of patients who frequently had been bitten by a triatomine 
bug on the face hence its namesake as kissing bugs. An estimated 8 million people in Mexico, 
Central and South America are infected with Chagas disease [2]. This vector borne parasitic 
infection is not limited to rural areas but has also been identified in urban areas. In this mod-
ern time, diaspora has been an effective vehicle in spreading this infection to different parts of 
the world. While other modes of infections have also been identified from ingesting contami-
nated food or drinks with the feces of the kissing bug [5] to blood transfusions [6], and organ 
transplantation [7, 8] as being incidental causes of parasite transmission.
4. Chagas disease: debilitating health impacts
Signs and symptoms of a person having Chagas disease may include fever, fatigue, malaise, 
and sometimes rash or edema (chagoma) around the eye during the acute phase while car-
diac and intestinal complication may present in less than 50% of those infected [2]. Infections 
persist throughout life and most infected individuals are not even aware that they carry the 
parasite. To date, there is no effective drug or vaccine that has been developed and vector 
control is still the main driving force for the parasite intervention.
The World Health Organization Fact sheet of 2017 outlines key information about Chagas dis-
ease. Approximately 6 to 7 million people worldwide are infected (mostly in Latin America) 
and some scientists even place estimates as high as 20 million. About 30% of chronic infections 
progress to cardiac implications and 10% to digestive tract abnormalities which are irrepa-
rable [9]. Chronic infections can lead to megaesophagus, megacolon, mega-small intestine, 
and mega gallbladder to name a few, other impairments of the gastrointestinal tract organs 
and tissues have been observed. A higher incidence of Helicobacter pylori infection, colon, and 
esophageal cancer has been demonstrated in association with trypanosomiasis as well [10]. 
Chronic chagasic cardiopathy on the other hand leads to cardiac lesions and the patient’s 
immune status and initial parasitemia are significant determinants of the gravity and progres-
sion to organ failure [11].
Chagas Disease - Basic Investigations and Challenges2
The estimated annual cost of medical care for trypanosomiasis patients in Colombia in 2008 
has been estimated to be 267 million US Dollars [9]. While a computational simulation model 
funded by the Bill and Melinda Gates Foundation has estimated the global economic burden 
to 7–19 billion US Dollars per year [10] and approximately 188 billion US Dollars per lifetime 
[11]. These figures are higher than the estimates for other prominent global diseases (rotavi-
rus 2.0 billion US Dollars, cervical cancer 4.7 billion US Dollars, and Lyme disease 2.5 billion 
US Dollars) [12]. Meanwhile, these estimated figures alone raise large red flags which the sci-
entific community and funding agencies should focus their attention again on trypanosomia-
sis. Although, naturally vector borne and localized in South America, this disease has found 
its way into several modes of transmissions and has spread and is continuously spreading in 
different parts of the world.
To date, there is still no vaccine against Chagas disease. Drug intervention with antiparasitic 
agents is only useful during the early phase of infection. Wherein, the signs and symptoms 
are usually misdiagnosed for other pathologic conditions or left undiagnosed altogether and 
if left undetected will consequently lead to debilitating conditions and mortality. For this 
reason, vector control and hygienic living conditions have been and should be a constant 
advocacy. Vector control cost estimates have been around 5 million US Dollars for spraying 
insecticides which is significantly less compared to risks in human well-being and accumu-
lated medical care bills annually and through a lifetime. Maintaining clean living conditions 
in a household and using bednets in sleeping areas [13] cost even less as a reasonable means 
of intervention from preventing kissing bug bites.
5. Concluding remarks
This book is dedicated to the millions who have fallen victims and those presently and heav-
ily burdened with Chagas disease. The contributors of the literatures herein contained for 
a significant time in their lives have become living witnesses to the ravage and devastation 
kissing bugs carrying T. cruzi can inflict upon an individual as well as a nation. These inves-
tigators have dedicated their time and being in so many different ways in their own personal 
and consolidated effort to provide the best, most comprehensive, and up to date knowledge 
to explore the American trypanosomiasis in all its available entirety. The chapters contained 
in this book will no doubt prove to be indispensable in getting up-close and personal into 
Chagas disease findings. Each chapter provides in-depth discussions of each specific area of 
historic, biologic, vector, and pathologic, along with clinical aspects, diagnostic challenges, 
natural products, drugs discovery, and various control measures as well as strategies relative 
to this very old yet still rampant and neglected parasitic infection. It is with great anticipation 
that this compilation of literature reviews and researches would find its way into the hands 
of experts as well as those novice who will soon be at the forefront of leading the fight against 
this debilitating infection. It is with great hope that this book will be a tool for the fruition of 
Chagas disease eradication.
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